Neogen international vice president Dr Jason Lilly and Australasia senior director Bobby Creasman with 100,000 chip samples about to be tested during the opening of Neogen’s Brisbane laboratory some years ago

ANIMAL health company Zoetis is to buy Neogen’s global animal genomics business in a deal worth US$160 million (A$238m).

A joint statement issued overnight said the acquisition aligned with Zoetis’ strategy to drive future livestock innovation through genomics, reinforcing its commitment to livestock producers worldwide and advancing its Precision Animal Health portfolio.

“By integrating Neogen’s genomic technologies and data solutions, Zoetis is expanding its capabilities to deliver predictive insights, individualized care, and greater value to customers across major livestock and companion animal species,” the statement said.

The message delivered in the deal is that Zoetis clearly sees the prediction component of the animal genomics space – where Neogen has established a strong footprint – as a growth opportunity.

Neogen’s genomics business serves customers in more than 120 countries through its five laboratories in Australia (opened in 2018), the United States, Brazil, China and the United Kingdom, as well as an office location in Canada.

The business leverages a comprehensive genotyping platform of fixed array and sequencing technologies, as well as software solutions that help customers make informed and data-driven decisions.

Both Zoetis and Neogen are active in the Australian animal genetics space, and the companies product offers are regarded as complementary.

Cutting-edge technologies

Neogen is a leader in US beef and dairy genomics, and its technologies enable highly accurate, scalable genetic testing and deeper insights into animal health, productivity and sustainability.

“The addition of Neogen’s genomics business strengthens our commitment to advancing animal health through innovation, data, and technology,” Zoetis’s chief commercial officer Jamie Brannan said.

“As we continue to grow our innovative solutions in Precision Animal Health, this acquisition brings complementary capabilities that expand predictive insights and individualised care, enabling us to deliver added value to customers. Together, we are shaping the future of animal health, empowering customers with the tools they need to support healthier animals and sustainable livestock production globally,” Mr Brannan said.

The deal is subject to customary US closing conditions and the satisfaction of regulatory requirements, and Zoetis expects to complete the acquisition in the second half of 2026.

Zoetis said it was committed to a seamless integration, supporting continuity for colleagues and customers, and building on Neogen’s legacy of innovation in genomics.

About Neogen

Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the food safety, livestock, and pet health & wellness markets. A world leader in these fields, Neogen has a presence in more than 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.